Original Article

Hepatitis C Transmission, Prevention, and Treatment Knowledge Among Patients with HIV

Authors: Rae Jean Proeschold-Bell, PhD, Rachel Blouin, MPH, Susan Reif, PhD, MSW, Arit Amana, MPH, Benjamin J. Rowland, BA, Frank Lombard, MSW, Beth Stringfield, BA, Andrew J. Muir, MD

Abstract

Objective: Liver disease associated with hepatitis C virus (HCV) is a serious cause of mortality among people living with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) (PLWHA). Little is known about the HCV knowledge of PLWHA.


Methods: One hundred seventy-nine patients at an infectious disease clinic were interviewed on HCV knowledge and alcohol use.


Results: Sixty-six percent of participants indicated that HCV is transmitted through blood; 53% indicated that persons with HIV-HCV co-infection can benefit from HCV treatment; and 79% and 74%, respectively, indicated that safer sex and safer injection techniques can prevent HCV transmission. Among PLWHA with self-reported HCV, 97% indicated that persons with HCV should not drink alcohol, but 32% reported using alcohol in the past 30 days.


Conclusions: Health education is needed to prevent HCV infections and increase HCV treatment-seeking. Higher education levels were related to more accurate HCV knowledge, indicating the need for health promotion for PLWHA of lower education levels.


Key Points


* People with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) need to know that hepatitis C (HCV) treatment exists for people with HIV/AIDS in order to encourage them to test for HCV, and, if HCV-infected, seek treatment.


* Education on the transmittal of HCV needs to be provided for HIV/AIDS patients so they might better protect themselves from HCV infection.


* The current study, conducted in central North Carolina, found that patients with HIV have large gaps in knowledge about HCV treatment and transmission and that unacceptably high numbers of patients with HIV-HCV co-infection drink alcohol.


* Individuals with HIV-HCV co-infection need strategies to avoid alcohol consumption.


* Efforts to educate patients with HIV may include medical providers and clinic social workers.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006;144:705–714.
 
2. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001;345:41–52.
 
3. Sherman KE, Roustrer S, Chung R, et al. Hepatitis C: prevalence in HIV-infected patients across sectional analysis of the US ACTG. Antivir Ther 2000;5(suppl 1):64–65.
 
4. Verucchi G, Calza L, Manfredi R, et al. Human immunodeficiency virus and hepatitis C virus coinfection: epidemiology, natural history, therapeutic options and clinical management. Infection 2004;32:33–46.
 
5. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001;32:492–497.
 
6. Weber R, Sabin CA, Friis-Møller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006;166:1632–1641.
 
7. Cribier B, Rey D, Schmitt C, et al. High hepatitis C viraemia and impaired antibody response in patients coinfected with HIV. AIDS 1995;9:1131–1136.
 
8. Soriano V, Sulkowski M, Bergin C, et al. Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. AIDS 2002;16:813–828.
 
9. Sánchez-Quijano A, Andreu J, Gavilán F, et al. Influence of human immunodeficiency virus type 1 infection on the natural course of chronic parenterally acquired hepatitis C. Eur J Clin Microbiol Infect Dis 1995;14:949–953.
 
10. Soto B, Sánchez-Quijano A, Rodrigo L, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997;26:1–5.
 
11. García-Samaniego J, Rodríguez M, Berenguer J, et al. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C.  Am J Gastroenterol 2001;96:179–183.
 
12. Rockstroh JK, Mocroft A, Soriano V, et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005;192:992–1002.
 
13. Ostapowicz G, Watson KJ, Locarnini SA, et al. Role of alcohol in the progression of liver disease caused by hepatitis C virus infection. Hepatology 1998;27:1730–1735.
 
14. Pessione F, Ramond MJ, Peters L, et al. Five-year survival predictive factors in patients with excessive alcohol intake and cirrhosis. Effect of alcoholic hepatitis, smoking and abstinence. Liver Int 2003;23:45–53.
 
15. Gitto S, Micco L, Conti F, et al. Alcohol and viral hepatitis: a mini-review. Dig Liver Dis 2009;41:67–70.
 
16. Hassan MM, Hwang LY, Hatten CJ, et al. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 2002;36:1206–1213.
 
17. Hézode C, Lonjon I, Roudot-Thoraval F, et al. Impact of moderate alcohol consumption on histological activity and fibrosis in patients with chronic hepatitis C, and specific influence of steatosis: a prospective study. Aliment Pharmacol Ther 2003;17:1031–1037.
 
18. Fernández-Rodriguez CM, Gutiérrez ML, Serrano PL, et al. Factors influencing the rate of fibrosis progression in chronic hepatitis C. Dig Dis Sci 2004;49:1971–1976.
 
19. Westin J, Lagging LM, Spak F, et al. Moderate alcohol intake increases fibrosis progression in untreated patients with hepatitis C virus infection. J Viral Hepat 2002;9:235–241.
 
20. Weaver MF, Cropsey KL, Fox SA. HCV prevalence in methadone maintenance: self-report versus serum test. Am J Health Behav 2005;29:387–394.
 
21. Walley AY, White MC, Kushel MB, et al. Knowledge of and interest in hepatitis C treatment at a methadone clinic. J Subst Abuse Treat 2005;28:181–187.
 
22. Carey J, Perlman DC, Friedmann P, et al. Knowledge of hepatitis among active drug injectors at a syringe exchange program. J Subst Abuse Treat 2005;29:47–53.
 
23. Heimer R, Clair S, Grau LE, et al. Hepatitis-associated knowledge is low and risks are high among HIV-aware injection drug users in three US cities. Addiction 2002;97:1277–1287.
 
24. Sachithanandan S, Kay E, Leader M, et al. The effect of light drinking on HCV liver disease: the jury is still out. Biomed Pharmacother 1997;51:295–297.
 
25. Grebely J, Genoway KA, Raffa JD, et al. Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. Drug Alcohol Depend 2008;93:141–147.
 
26. Campbell JV, Hagan H, Latka MH, et al. High prevalence of alcohol use among hepatitis C virus antibody positive injection drug users in three US cities. Drug Alcohol Depend 2006;81:259–265.
 
27. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm Rep 1998;47:1–39.
 
28. Silk KJ, Horodynski MA, Rienzo M, et al. Strategies to increase health literacy in The Infant Feeding Series (TIFS): a six-lesson curriculum for low-income mothers. Health Promot Pract 2010;11:226–234.
 
29. Aberg JA, Gallant JE, Anderson J, et al. Primary care guidelines for the management of persons infected with human immunodeficiency virus: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2004;39:609–629.